SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
1-Year Return
18.23%
This Quarter Return
-7.14%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.28B
AUM Growth
-$45.7M
(-3.5%)
Cap. Flow
+$95.6M
Cap. Flow
% of AUM
7.5%
Top 10 Holdings %
Top 10 Hldgs %
50.86%
Holding
98
New
17
Increased
22
Reduced
20
Closed
23
Top Buys
| 1 |
NovoCure
NVCR
|
$49.6M |
| 2 |
STAAR Surgical
STAA
|
$45.2M |
| 3 |
BBNX
Beta Bionics, Inc. Common Stock
BBNX
|
$41.6M |
| 4 |
Praxis Precision Medicines
PRAX
|
$33.9M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$18.7M |
Top Sells
| 1 |
Axogen
AXGN
|
$27.9M |
| 2 |
AstraZeneca
AZN
|
$26.8M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$25.2M |
| 4 |
QuidelOrtho
QDEL
|
$24.4M |
| 5 |
Adaptive Biotechnologies
ADPT
|
$22.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
ANI Pharmaceuticals
ANIP
$2.06B
| $15M | 1.08% |
224,684
+19,390
| +9% | +$1.3M |
|
|
EDAP
27
EDAP TMS
EDAP
$102M
| $14.3M | 1.03% |
7,309,254
| – | – |
|
28
Inhibikase Therapeutics
IKT
$124M
| $13.9M | 1% |
6,325,000
| – | – |
|
29
Evolus
EOLS
$492M
| $13M | 0.93% |
1,079,158
+382,000
| +55% | +$4.6M |
|
30
Pharvaris
PHVS
$1.4B
| $12.8M | 0.92% |
814,652
| – | – |
|
31
Sanofi
SNY
$114B
| $12.5M | 0.9% |
+226,218
| New | +$12.5M |
|
32
C4 Therapeutics
CCCC
$193M
| $11.2M | 0.8% |
6,978,942
| – | – |
|
33
Soleno Therapeutics
SLNO
$3.84B
| $10.7M | 0.77% |
+150,000
| New | +$10.7M |
|
34
Kiniksa Pharmaceuticals
KNSA
$2.71B
| $10.4M | 0.75% |
+469,500
| New | +$10.4M |
|
35
Arcellx
ACLX
$3.94B
| $10M | 0.72% |
153,031
+32,000
| +26% | +$2.1M |
|
36
Syndax Pharmaceuticals
SNDX
$1.41B
| $10M | 0.72% |
816,610
-1,675,390
| -67% | -$20.6M |
|
37
Orthofix Medical
OFIX
$581M
| $9.82M | 0.71% |
601,925
-84,449
| -12% | -$1.38M |
|
38
Tandem Diabetes Care
TNDM
$845M
| $9.5M | 0.68% |
+496,039
| New | +$9.5M |
|
39
Scholar Rock
SRRK
$3.04B
| $9.16M | 0.66% |
285,000
+117,457
| +70% | +$3.78M |
|
40
Ascendis Pharma
ASND
$12.4B
| $8.77M | 0.63% |
56,300
-87,700
| -61% | -$13.7M |
|
41
Protagonist Therapeutics
PTGX
$3.5B
| $8.17M | 0.59% |
169,000
-106,000
| -39% | -$5.13M |
|
42
Immunic
IMUX
$81.6M
| $7.95M | 0.57% |
7,293,007
| – | – |
|
43
CG Oncology
CGON
$2.57B
| $7.43M | 0.54% |
303,585
-25,000
| -8% | -$612K |
|
|
44
Teva Pharmaceuticals
TEVA
$22.1B
| $6.92M | 0.5% |
450,500
-1,642,500
| -78% | -$25.2M |
|
|
THTX
45
Theratechnologies
THTX
$150M
| $6.72M | 0.48% |
4,801,376
| – | – |
|
46
Jasper Therapeutics
JSPR
$43.1M
| $6.43M | 0.46% |
1,494,420
| – | – |
|
47
Inspire Medical Systems
INSP
$2.47B
| $6.21M | 0.45% |
+39,000
| New | +$6.21M |
|
48
Verastem
VSTM
$630M
| $5.64M | 0.41% |
935,909
-1,248,117
| -57% | -$7.53M |
|
49
Akero Therapeutics
AKRO
$3.57B
| $4.74M | 0.34% |
+117,000
| New | +$4.74M |
|
50
LivaNova
LIVN
$3.18B
| $4.6M | 0.33% |
+117,040
| New | +$4.6M |
|